FAQ  /  Women's Hormone Health

I've Had a Hysterectomy. Do I Still Need Progesterone With My Estrogen?

Hysterectomy Removes the Uterus, Not Necessarily Every Endometrial Cell

---

Endometriosis is endometrial-type tissue growing outside the uterus. It carries estrogen and progesterone receptors and it responds to circulating estrogen the way the uterine lining does, by proliferating.

A woman can have endometriosis she never knew about. It can be present without pain, without heavy periods, without infertility, and without ever having been looked for, because nobody was searching for it during a surgery performed for another reason.

If that tissue is still present and estrogen is given without progesterone, the tissue receives a sustained proliferative signal with nothing opposing it and no monthly shedding to interrupt it. In rare cases that ends in malignant transformation of the focus itself. When that happens, it is usually an endometrioid adenocarcinoma arising in the endometriosis. It is not cancer of the uterus, which is no longer there.

A related situation is worth knowing about. A supracervical hysterectomy leaves the cervix, and residual endometrial tissue in the cervical stump is a recognized finding. Women are not always told which operation they had.

How Often Is That Tissue There Without Anyone Knowing

---

More often than most people expect.

The cleanest way to estimate this is to look at what surgeons find incidentally in women having laparoscopic tubal sterilization, since those women typically have no gynecologic complaints. Across seventeen published series the reported prevalence ranges from 1.4 to 43.3 percent. A prospective series of 465 sterilizations performed by a single surgeon found endometriosis in 11.8 percent, confirmed on pathology in 91 percent of those cases, almost all of it minimal disease. An older study that deliberately looked for the subtle, non-classic lesions found evidence of endometriosis in 45 percent of asymptomatic women.

The width of that range says more about how hard anyone was looking than about how much disease exists. Even the low end is not rare.

What Has Actually Been Reported

---

The cases are few, they are decades apart, and they are consistent.

In 1988, two women were described who developed malignancy in a dormant focus of endometriosis after total abdominal hysterectomy, removal of both ovaries, and estrogen replacement. The authors concluded that adding a progestin to replacement therapy in such women may reduce that risk.

In 2004, two more were reported, with adenocarcinoma following disseminated pelvic endometriosis, three and thirteen years after hysterectomy, both on estrogen alone.

A Mayo Clinic series examined 31 patients whose cancer developed from endometriosis, each matched to two women who had endometriosis without cancer. Fifteen were obese and nine were taking unopposed estrogen. Neither unopposed estrogen nor obesity reached statistical significance on its own. Only when the two were considered together did the difference reach significance, at a p value of 0.05. That is a trend in a small retrospective study rather than a demonstration.

The most recent series, published in 2020, described ten patients with malignant transformation of endometriosis outside the ovary. Six of the tumors were endometrioid adenocarcinoma, and four of the ten women had received estrogen-only hormone therapy after hysterectomy and removal of both ovaries.

Why the Guidelines Appear to Disagree

---

Because two different sets of guidelines are answering two different questions, and most people have only read one of them.

The menopause guidelines address the woman after hysterectomy in general terms and conclude that a progestogen is not required. Their language is permissive rather than prohibitive: estrogen-alone therapy can be used for symptomatic women without a uterus, and a progestogen is added to provide endometrial protection when a uterus is present. They do not say a woman without a uterus should avoid progesterone.

They also do not mention endometriosis. The 2022 position statement of The North American Menopause Society runs to 28 pages and the word does not appear in it. That is a matter of scope rather than disagreement, and it is why a clinician reading only that document would never encounter the question this page is about.

The European endometriosis guideline, updated in 2022, does address it and says so firmly. It carries a strong recommendation that estrogen-only regimens should be avoided in postmenopausal women with a history of endometriosis, because of the risk of malignant transformation, and it adds that women who went through surgical menopause should stay on combined estrogen and progestogen at least until the age of natural menopause. That recommendation rests on a 2017 systematic review of menopause management in women with endometriosis.

For a woman with known endometriosis, progesterone is not an unusual addition. Estrogen alone is the departure.

The open question is the woman whose endometriosis was never diagnosed. No study has randomized that group, and none is likely to.

The Study People Cite Against This, and What It Actually Used

---

The Women's Health Initiative is the trial that gets raised here, and it deserves a direct answer.

In the arm of that trial studying women who had already had a hysterectomy, estrogen alone was associated with lower breast cancer incidence than placebo, a hazard ratio of 0.78, and lower breast cancer mortality, a hazard ratio of 0.60, over more than twenty years of follow-up. In the arm studying women with a uterus, estrogen combined with a progestogen was associated with higher breast cancer incidence, a hazard ratio of 1.28.

Read quickly, that appears to argue against adding anything to estrogen. The detail that changes the reading is what was added. The trial used medroxyprogesterone acetate, a synthetic progestin, not progesterone. The menopause society's own position statement makes this point directly, saying it is unknown whether therapy containing micronized progesterone similarly increases the risk of breast cancer, stroke, gallbladder disease, heart attack, or blood clots, because trials have not been designed to examine those outcomes. It also notes that micronized progesterone may be less thrombogenic than other progestins.

The picture is different with micronized progesterone. In the French E3N cohort, which followed more than 80,000 postmenopausal women and recorded the incidence of invasive breast cancer, the combination of estradiol with progesterone carried a relative risk of 1.00, with a confidence interval of 0.83 to 1.22, meaning no detectable increase compared with women who had never used hormone therapy. Estrogen with dydrogesterone was 1.16, and estrogen with other progestins 1.69. A review of this question in Endocrine Reviews noted that estrogen alone, estrogen with progesterone, and estrogen with dydrogesterone did not differ significantly from one another, while all three carried significantly lower risk than estrogen combined with other progestins.

A separate analysis of United Kingdom primary care records, 43,183 women with breast cancer matched against 431,830 without it, found the same pattern. Micronized progesterone carried an odds ratio of 0.99 and synthetic progestins 1.28, and the authors concluded that micronized progesterone may be the safer progestogen.

What is not yet settled is long-duration use. The analyses above drew on populations whose average time on treatment was a few years, and the evidence beyond five years is limited and not consistent across datasets. That is a gap in the evidence rather than a finding, and it is a reason to reassess periodically rather than to treat any regimen as permanent.

The pattern repeats outside the breast. In a case-control study of venous thromboembolism, micronized progesterone showed no association with clot risk, an odds ratio of 0.7, while norpregnane progestins carried an odds ratio of 3.9. In a three-year randomized trial, micronized progesterone preserved the rise in HDL cholesterol that estrogen produced, while medroxyprogesterone acetate blunted it. In primates, medroxyprogesterone acetate abolished the reduction in coronary plaque that estrogen alone achieved.

Bone Is a Two-Hormone Job

---

This is the part most often left out, and it is a reason to consider progesterone entirely separate from the endometriosis question.

Bone is not static tissue. It is continuously broken down by osteoclasts and rebuilt by osteoblasts, and healthy bone depends on both halves of that cycle. Estradiol and progesterone divide the work. Estradiol acts principally on the breakdown side, restraining resorption. Progesterone acts on the building side, on the osteoblast.

Human osteoblasts carry both isoforms of the progesterone receptor. In cultured primary human osteoblasts, progesterone drove differentiation with a dose-response that peaked at concentrations matching the luteal phase of a normal menstrual cycle, and the effect fell away at concentrations above physiologic range. Estradiol and progesterone together also upregulate insulin receptor substrate-2 in human osteoblasts, a protein that matters for bone formation, which is cooperation at the level of gene expression rather than merely two drugs given at once.

The reason these are partners rather than alternatives shows up when either is given alone. Progesterone by itself does not prevent postmenopausal bone loss. Across the placebo-controlled trials, bone changed by about 2.2 percent per year on progesterone or a progestin against 2.4 percent per year on placebo, which is no meaningful difference. The explanation from the bone literature is that formation effects can raise bone density only when resorption is normal, and progesterone does not restrain resorption. Estrogen does. So estrogen without progesterone leaves formation under-stimulated, and progesterone without estrogen cannot build faster than unchecked breakdown removes.

Given together, the combination outperforms estrogen alone at the spine. In a two-year randomized double-blind placebo-controlled trial in 822 early postmenopausal women, spine bone density rose 3.46 percent on conjugated estrogen 0.625 mg with a progestin against 2.43 percent on the same estrogen dose alone, and 3.01 against 2.09 percent at the 0.45 mg estrogen dose. Both differences were statistically significant. A meta-analysis of five trials that directly randomized more than a thousand women to estrogen or estrogen with a progestogen found spinal bone density gain greater by 0.68 percent per year on the combination.

Three qualifications belong with that. The randomized evidence for the added spinal gain used medroxyprogesterone acetate rather than micronized progesterone, and in the PEPI trial the micronized progesterone arm did not show a significant bone effect on its own. The advantage appears at the spine and not at the hip. And no trial has compared fracture rates between estrogen alone and estrogen with a progestogen, so the outcome that matters most has not been measured. Estrogen remains the primary bone-active hormone. The case for adding progesterone is that it works on the half of bone remodeling estrogen does not.

What Else Progesterone Does

---

Progesterone is converted to allopregnanolone, which acts at the GABA-A receptor, the same receptor family that benzodiazepines and sleep medications act on. That conversion happens largely during first pass through the liver, which is why an oral dose produces the effect and a transdermal one largely does not, and why the dose is usually taken about an hour before bed.

In postmenopausal women, oral micronized progesterone reduced time spent awake during the night, and in a separate trial restored deep sleep when sleep had been disrupted, without suppressing slow-wave sleep the way conventional sleep medications tend to. It also reduced hot flashes and night sweats in a randomized trial in postmenopausal women.

How This Gets Decided

---

None of this makes progesterone mandatory after hysterectomy. The absolute risk of malignant transformation in residual endometriosis is low, which is exactly why the general menopause guidelines do not require it.

What it does mean is that the decision deserves an actual conversation rather than a reflexive no. A woman weighing this is entitled to know that the tissue in question may be present without her knowing, that the case reports exist, that the endometriosis guideline and the menopause guidelines cover different ground, that the trial most often cited against it studied a different molecule, and that progesterone has bone and sleep effects independent of any of that.

A woman who considers all of it and declines has made a reasonable decision. What matters is that it was hers to make, with the reasoning in front of her.

Dr. Darrell Wilcox · @wellnessdoc_4everyoung on Instagram

This content is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Estrogen and progesterone are prescription treatments with their own indications, contraindications, and monitoring requirements, and any decision about what belongs in a hormone regimen should be made with your own physician, who has your surgical history and pathology in front of them. Individual results differ from trial averages, and the studies described here were conducted in specific populations that may not match your own situation. Dr. Wilcox is licensed to practice in multiple states. See About for current licensure.